Cansino Biologics Stock Fundamentals
| CJH Stock | 3.66 0.12 3.17% |
CanSino Biologics fundamentals help investors to digest information that contributes to CanSino Biologics' financial success or failures. It also enables traders to predict the movement of CanSino Stock. The fundamental analysis module provides a way to measure CanSino Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CanSino Biologics stock.
CanSino |
CanSino Biologics Company Shares Outstanding Analysis
CanSino Biologics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current CanSino Biologics Shares Outstanding | 114.78 M |
Most of CanSino Biologics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CanSino Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, CanSino Biologics has 114.78 M of shares currently outstending. This is 36.42% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers-Specialty & Generic industry. The shares outstanding for all Germany stocks is 79.93% higher than that of the company.
CanSino Biologics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CanSino Biologics's current stock value. Our valuation model uses many indicators to compare CanSino Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CanSino Biologics competition to find correlations between indicators driving CanSino Biologics's intrinsic value. More Info.CanSino Biologics is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CanSino Biologics' earnings, one of the primary drivers of an investment's value.CanSino Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CanSino Biologics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CanSino Biologics could also be used in its relative valuation, which is a method of valuing CanSino Biologics by comparing valuation metrics of similar companies.CanSino Biologics is currently under evaluation in shares outstanding category among its peers.
CanSino Fundamentals
| Return On Equity | 0.0111 | |||
| Return On Asset | -0.0207 | |||
| Current Valuation | 3.4 B | |||
| Shares Outstanding | 114.78 M | |||
| Shares Owned By Insiders | 26.70 % | |||
| Shares Owned By Institutions | 38.77 % | |||
| Price To Book | 2.25 X | |||
| Price To Sales | 2.17 X | |||
| Revenue | 4.3 B | |||
| Gross Profit | 1.03 B | |||
| EBITDA | 2.05 B | |||
| Net Income | 1.91 B | |||
| Total Debt | 40 M | |||
| Book Value Per Share | 29.22 X | |||
| Cash Flow From Operations | 2.05 B | |||
| Earnings Per Share | 0.52 X | |||
| Beta | 0.61 | |||
| Market Capitalization | 3.2 B | |||
| Total Asset | 11.87 B | |||
| Z Score | 47.4 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 11.87 B |
About CanSino Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CanSino Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CanSino Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CanSino Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for CanSino Stock Analysis
When running CanSino Biologics' price analysis, check to measure CanSino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CanSino Biologics is operating at the current time. Most of CanSino Biologics' value examination focuses on studying past and present price action to predict the probability of CanSino Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CanSino Biologics' price. Additionally, you may evaluate how the addition of CanSino Biologics to your portfolios can decrease your overall portfolio volatility.